BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Quick Stats
Jan 30, 202650.2
AI Score
HOLD0.98
Volume Ratio
Mar 19, 2026
Next Earnings
10
+ve Days (30d)
20
-ve Days (30d)
BCAB Stock Summary
Last updated Jan 30, 2026
BCAB is currently trading at $0.269, positioned below its 200-day moving average of $0.54, suggesting bearish momentum. The stock has a 52-week range of $0.24 to $1.43.
Technical Analysis: The 50-day moving average stands at $0.64, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 28.81, suggesting the stock is oversold and potentially undervalued.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.422, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates BCAB at 50.2/100 with a HOLD recommendation.
BCAB (BioAtla, Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 28.81 |
| CMF (20) | -0.422 |
| ROC (10) | -15.832 |
| ADX (14) | 33.52 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.092 |
| AROONOSC (14) | -85.714 |
| WILLAMS %R (14) | -89.809 |
| MFI (14) | 30.95 |
BCAB Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
BCAB Price vs Max Options Open Interest
BCAB Max Change In Options Open Interest
BCAB Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BCAB Daily Out of Money Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BCAB Daily In the Money Options - Sort by Max open Interest (near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BCAB Most Active Options by Volume(near term)
1st February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BioAtla, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
BCAB Moving Averages Analysis
BCAB (BioAtla, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 0.31 |
| 20 | 0.35 |
| 30 | 0.48 |
| 50 | 0.64 |
| 100 | 0.68 |
| 200 | 0.54 |
BCAB Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 17.2 million |
| Earnings/Share ($) | -1.07 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -1.08 |
| EPS Estimate Next Year ($) | -0.92 |
| WallStreet Target Price ($) | 10 |
| Most Recent Quarter |